NetworkNewsWire Editorial
Coverage: Double 2001 levels,
Americans spent over $36 billion on vitamins and nutritional
supplements in 2016, contributing to a global dietary supplements
market expected to exceed $220 billion by the year 2022 (http://nnw.fm/z8Bh1, http://nnw.fm/qARU7). A noteworthy characteristic of
products within this booming sector is bio-absorbability. In order
for the body to utilize vitamins and minerals, they must
disintegrate and be quickly released. Otherwise, they are simply
excreted, rendering them ineffectual. A recent study revealed that
over half of encapsulated micronutrients didn’t disintegrate within
the time needed for effective absorption (http://nnw.fm/12CAq), demonstrating a sizable
underserved need within the multi-billion-dollar industry.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB:
LXRP) (LXRP
Profile) has developed and patented a
cost-effective lipophilic technology that addresses this issue,
serving as a delivery platform for all cannabinoids, fat soluble
vitamins, non-steroidal anti-inflammatory pain medications
(“NSAIDs”), and even nicotine. With proven efficacy for improved
taste, rapidity, and delivery of bioactive compounds, Lexaria is
positioned to license its technology to tobacco giants such as
Philip Morris International, Inc.
(NYSE: PM) and
British American Tobacco PLC
(NYSE: BTI), as well as
cannabinoid biopharmaceutical companies like GW
Pharmaceuticals PLC (NASDAQ: GWPH) and major drug
companies such as Pfizer, Inc. (PFE).
Adding to its portfolio of 19 international patent applications
filed encompassing 44 countries, Lexaria
Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) earlier this
week announced that it has received from the United States Patent
and Trademark Office (“USPTO”) a new Notice of Allowance that
applies to the delivery of all applied-for active pharmacological
ingredients (“APIs”). As was the case with Lexaria’s existing
non-psychoactive cannabinoid patent, the company expects formal
patent issuance within three to four months, which is expected to
provide protection until at least 2035.
The issuance of the patent will enable Lexaria to accelerate its
technology out-licensing activities in several key markets. The
irony is that this R&D that originated in the cannabis is now
finding use in delivery of NSAIDs, vitamins and even nicotine.
“This wide-ranging patent allowance from the USPTO exceeds our
expectations. This vastly expanded intellectual property protection
will enable us to aggressively pursue new business opportunities in
2018 such as what could be the world’s first nicotine edibles for
the smokeless tobacco industry, or enhanced products for
NSAID-derived pain management, as well as in the rapidly growing
cannabis market,” Lexaria CEO Chris Bunka stated in the press
release announcing the news (http://nnw.fm/2iPIn).
According to the CDC, 36.5 million adults in the U.S. currently
smoke tobacco, while 16 million live with a smoking-related
disease. The U.S. FDA earlier this year submitted a proposal to
reduce nicotine levels in cigarettes to non-addictive levels in an
effort to significantly reduce the effects of tobacco-related
diseases. As such, leading tobacco companies are pursuing
marketable alternatives to their combustible offerings, and Lexaria
is uniquely positioned to capture a share of this mammoth market
with technology allows that for the infusion of nicotine molecules
within a wide range of edible food ingredients or capsules.
Notably, current forms of nicotine delivery have mostly failed.
The development of readily absorbed nicotine-infused edible
products could create smoke-free cigarette alternatives and greatly
improve upon the success of inhalation smoking cessation
programs. The expected FDA action makes tobacco giant
Philip Morris International Inc. (PM), which
manufactures and sells cigarettes and other tobacco products
globally, a potential licensee for edible, absorbable nicotine
replacement therapeutics.
Another potential tobacco company beneficiary of Lexaria’s
technology is British American Tobacco PLC (BTI),
which has invested more than $1 billion in building its “Next
Generation Products” business, an assortment of alternative tobacco
and nicotine products aimed at reducing the risks associated with
smoking conventional cigarettes. Looking to the future, BTI was
among the first international tobacco companies to launch an
e-cigarette product in the UK. Touted as a tobacco alternative,
electronic cigarettes still rely on inhalation for nicotine
delivery, and the long-term health risk associated with
e-cigarettes remains in question. Bio-absorbable nicotine could
provide much safer and less expensive molecule delivery.
Lexaria’s potential in this market is best understood by
examining the application of the company’s technology to
cannabinoids, as well as its licensing strategy.
Medical cannabinoids have demonstrated therapeutic efficacy for
a variety of diseases and ailments; however, the human
gastrointestinal tract doesn’t absorb cannabinoids easily, causing
wide deviation in onset times and effectiveness. To achieve higher
effectiveness, consumers usually default to smoking. The key
differentiator between Lexaria’s technology and older tech on the
market is its ability to enhance the absorption of orally-ingested
cannabinoids while improving the “unusual” taste and allowing for
lower overall dosing with higher efficacy. Furthermore, Lexaria’s
lipophilic enhancement technology increases the bio-absorption of
cannabinoid edibles to between five and ten times that of
inhalation and reduces onset times by roughly 75% due to rapid
bio-absorption and potential liver bypass.
In what will only be strengthened by issuance of the aforenoted
patent, Lexaria uses a low-cost, high-margin license and royalty
model of revenue generation. Since its technology is complimentary
to all ingested forms of cannabinoids and potentially multiple
other ingestible products, the company is positioned to license its
intellectual property to biopharmaceutical companies as a partner
rather than a competitor. In short, the enhanced technology
provides an additional layer of effectiveness designed to harmonize
with the intellectual property of third parties, such as GW
Pharmaceuticals PLC (NASDAQ: GWPH), as they deliver
best-in-class products to their existing large consumer groups.
GW Pharmaceuticals is the world’s largest cannabinoid
pharmaceutical company. Recognized for its multiple sclerosis (MS)
cannabinoid product, Sativex, GW Pharmaceuticals is developing and
commercializing multiple therapeutics from its cannabinoid product
platform across a range of disease areas. The company's lead
cannabinoid product candidate, Epidiolex, a liquid formulation of
pure plant-derived cannabidiol (CBD), is in phase III clinical
trials for the treatment of severe treatment-resistant epilepsy
syndromes. Preliminary results from the trials have produced
encouraging results and, if approved, could bring in blockbuster
sales.
Beyond the cannabinoid sector, Lexaria sees considerable
potential in applying its delivery technology to many other
consumer products, including NSAIDs like Advil. More than 70
million prescriptions and more than 30 billion over-the counter
tablets of NSAIDs are sold annually in the United States alone.
While NSAIDs are effective in relieving pain, fever and
inflammation, they can cause unwanted and sometimes dangerous side
effects. Given a timely and predictable delivery system,
biopharmaceutical giant Pfizer (NYSE: PFE), the
maker of Advil, could easily find multiple applications for
Lexaria’s technology throughout its global portfolio of medicines,
vaccines and consumer health care products.
Lexaria is gaining considerable market traction with its
expanding patent portfolio, leveraging a unique technology that
positions the company as a potential partner to some of today’s
leading consumer brands. Building on this opportunity, Lexaria
continues to explore additional technologies that could deliver
value to its growing portfolio of patented technologies which now
has to be considered one of the broadest in the industry.
For more information on Lexaria Bioscience
Corp., please visit: Lexaria
Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From Nov 2023 to Nov 2024
